News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
Clinical - Phase III
Amgen (AMGN) Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis 9/16/2014
Bayer HealthCare Pharmaceuticals (BAYA.F) And Orion Corporation Initiate Phase 3 Trial Of ODM-201 In Men With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer 9/16/2014
OncoGenex Pharmaceuticals Inc. (OGXI) Announces Completion Of Patient Enrollment In The Phase 3 AFFINITY Trial Of Custirsen In Combination With Cabazitaxel/Prednisone As Second-Line Chemotherapy In Men With Metastatic Castrate-Resistant Prostate Cancer 9/16/2014
CSL Behring Announces Last Patient Treated In Phase 3 Study Of Fibrinogen Concentrate To Control Bleeding During Aortic Aneurysm Surgery 9/16/2014
Boehringer Ingelheim Corporation Release: Type 2 Diabetes: Investigational Empagliflozin/Linagliptin Combination Tablet Shows Sustained Reduction In Blood Glucose In Phase 3 Study 9/16/2014
Regeneron Pharmaceuticals, Inc. (REGN) Wins Breakthrough Therapy Designation From FDA For EYLEA 9/16/2014
Analyst: Safety Worries Dog Merck & Co. (MRK)’s Osteoporosis Drug 9/16/2014
Merck & Co. (MRK)'s Long-Delayed Osteoporosis Drug Passes Trial 9/16/2014
Agile Therapeutics, Inc. Initiates Phase 3 SECURE Study For Twirla™ 9/16/2014
ZS Pharma (ZSPH) Presents New Data From ZS003 A Two Week Phase 3 Trial Demonstrating That ZS-9 Prevented Recurrence Of Hyperkalemia In Heart Failure Patients On RAASi 9/16/2014
Relypsa, Inc. (RLYP) Announces New Analysis Of Phase 3 Data Demonstrating Patiromer's Ability To Rapidly Correct, And Prevent Recurrence Of, Hyperkalemia In Heart Failure And Non-Heart Failure Patients 9/16/2014
Mylan Inc. (MYL) Commences Phase 3 Clinical Trials For Its Generic Version Of Advair Diskus® And Insulin Analog To Lantus® 9/16/2014
Roche (RHHBY) Starts Pivotal Late-Stage Trial For Eye Drug Lampalizumab 9/15/2014
Cardio3 BioSciences Receives Approval For The Continuation Of Its Chart-1 Phase III Clinical Trial From The DSMB 9/15/2014
OSE Pharma Release: Texopi®, A New Ray Of Hope For Lung Cancer Immunotherapy 9/15/2014
Amgen (AMGN) Presents Analyses Of Phase 3 Ivabradine Data For The Treatment Of Chronic Heart Failure 9/15/2014
TG Therapeutics, Inc. (MHA) Announces Special Protocol Assessment (SPA) Agreement With The FDA For Its First Phase 3 Clinical Trial Of TG-1101 (Ublituximab) In Combination With Imbruvica(R) (Ibrutinib) For Patients With Previously Treated Chronic Lymphocytic Leukemia 9/15/2014
Eli Lilly and Company (LLY)'s Cyramza Met Primary Endpoint In Phase 3 Study 9/12/2014
Intarcia Therapeutics, Inc. Announces Two Presentations At 50th EASD Meeting: Confirms Pivotal Phase 3 Data Announcement For ITCA 650 In Type 2 Diabetes In 4Q 9/12/2014
Detailed Results From Biogen Idec, Inc. (Massachusetts) (BIIB) And AbbVie (ABBV)’s Pivotal Phase 3 Decide Study Further Define The Efficacy And Safety Profile Of ZINBRYTA™ (Daclizumab High-Yield Process) 9/12/2014
AbbVie (ABBV)'s Phase 3 Trial Of Humira Meets Primary Endpoint 9/12/2014
Sanofi (France) (SAN.PA)'s Genzyme Corporation (GENZ) Report Positive New Data From Lemtrada Multiple Sclerosis Trial 9/12/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: PLEGRIDY™ (Peginterferon Beta-1a) Two-Year Data Confirm Maintenance Of Efficacy And Safety In Multiple Sclerosis Patients 9/11/2014
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: New Data From ENDORSE Show Positive Results Continued Over Five Years With TECFIDERA® (Dimethyl Fumarate) In A Wide Range Of Multiple Sclerosis Patients 9/11/2014
ZS Pharma (ZSPH) To Present Data From Phase 3 Trial Of ZS-9 In Late-Breaking Session At Heart Failure Society Of America 18th Annual Scientific Meeting 9/11/2014
Mologen AG (MOLGF.PK): Initiation Of Phase 3 IMPALA Study With Immunotherapy MGN1703 In Colorectal 9/11/2014
GlaxoSmithKline (GSK) Takes Lead In New Wave Of Biotech Lung Drugs As Mepolizumab Performs In Phase 3 Study 9/10/2014
Thoratec Corporation (THOR) Announces Start Of Heartmate 3™ U.S. Clinical Trial 9/10/2014
Nymox Pharmaceutical (NYMX) Announces Positive Prostate Cancer 8 Month Clinical Trial Results 9/10/2014
AcelRx Pharmaceuticals (ACRX) Announces Publication Of Manuscript Analyzing Cost Of Intravenous Patient-Controlled Analgesia With Opioids 9/10/2014
Eisai Inc. (ESALF.PK) Release: Lorcaserin HCl Data To Be Presented At The American Society of Bariatric Physicians' 64th Annual Obesity & Associated Conditions Symposium 9/10/2014
SANUWAVE, Inc. Receives Information From The Data Monitoring Committee On The Dermapace Clinical Trial 9/10/2014
University of Minnesota Masonic Cancer Center Joins CEL-SCI (CVM)’s Phase 3 Head & Neck Cancer Trial 9/10/2014
Evoke Pharma, Inc. Announces The Completion Of Enrollment In Its Thorough ECG Study For EVK-001 9/9/2014
PTC Therapeutics, Inc. (PTCT) Completes Enrollment Of Landmark Trial In Duchenne Muscular Dystrophy 9/9/2014
Charleston Laboratories, Inc. Announces Key Clinical Updates For Novel Drugs 9/9/2014
Spectrum Pharmaceuticals, Inc. (SPPI) Makes Decision To Advance SPI-2012, A Novel Long-Acting GCSF, To Phase 3 Due To Positive Phase 2 Results In Its Collaboration Program With Hanmi Pharmaceutical, Co., Ltd 9/9/2014
Purdue Pharma L.P. Release: New Research Highlights An Investigational Single-Entity Formulation Hydrocodone Bitartrate Extended-Release Tablet At PAINWeek 9/8/2014
Sosei Group Corporation Announces Positive Results For Ultibro® And Seebri® Presented At ERS 2014, And Promotion Agreement With Pfizer Inc. (PFE) In The UK 9/8/2014
Vital Therapies, Inc. (VTI) (VTL) Announces Management Addition; Enrollment In VTI-208 Phase 3 Trial Now 75 Percent Complete 9/8/2014
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Reports On PK Profile Of A Single Oral Dose Of Delafloxacin In Support Of U.S. Phase 3 Gonorrhea Program 9/8/2014
Relypsa, Inc. (RLYP) Announces Phase 3 Patiromer Data To Be Presented In Late-Breaking Session At Heart Failure Society Of America 18th Annual Scientific Meeting 9/8/2014
Skyepharma PLC (SKYEF)’s Partner Mundipharma AG Announces Results Of Pivotal Phase III Study For Flutiform® In Paediatric Asthma 9/8/2014
Celsion Corporation (CLSN) Announces Highlights From Three Presentations Given At The International Liver Cancer Association 2014 Annual Conference 9/8/2014
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Demonstrate Delafloxacin's Potent And Rapid Antimicrobial Activity Against Neisseria Gonorrhoeae 9/8/2014
Evotec AG (EVTG.F) Announces Update On DiaPep277® 9/8/2014
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Phase 3 Study Shows Investigational Tiotropium Improves Lung Function In Adolescent Patients With Symptomatic Asthma 9/8/2014
Successful Completion Of Phase 3 Program For Teva Pharmaceutical Industries Limited (TEVA)’s Reslizumab Two More Phase Iii Studies Support The Benefits Of Reslizumab Treatment In Asthma Patients With Eosinophilia 9/8/2014
Boehringer Ingelheim Corporation Release: TONADO™ - Further Lung Function And Quality Of Life Benefits With Tiotropium + Olodaterol Respimat® FDC* In COPD 9/8/2014
Eli Lilly and Company (LLY)'s Diabetes Drug Trumps Sanofi (France) (SAN.PA)'s In Phase 3 Trials 9/5/2014
AcelRx Pharmaceuticals (ACRX) Announces Publication Of Sufentanil Sublingual Tablet System Vs. Intravenous Patient-Controlled Analgesia With Morphine For Postoperative Pain Study Results 9/5/2014
Exelixis, Inc. (EXEL) Chops 70 Percent Of Workforce After Prostate Drug Cabozantinib Fails Pivotal Study 9/4/2014
Novartis AG (NVS)'s New Heart Drug Cuts Cardiovascular Death Risk By 20 Percent; "Most Exciting Ever" Med Points To Huge Sales 9/4/2014
Flexion Therapeutics (FLXN) To Start FX006 Phase 3 Pivotal Trial In 2014; Following FDA Meeting, Development Plan Advanced By One Year 9/4/2014
Celgene Corporation (CELG) Release: Phase III FIRST™ (MM-020/IFM 07-01) Trial Of REVLIMID® (lenalidomide) Plus Dexamethasone In Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates For Stem Cell Transplant Published In New England Journal Of Medicine 9/4/2014
FDA Grants Fast Track Designation To Aradigm Corporation (ARDM)’s Pulmaquin For Non-Cystic Fibrosis Bronchiectasis 9/4/2014
Final Landmark Trial Confirms Efficacy Of Sanofi (France) (SAN.PA)'s Dengue Vaccine 9/3/2014
San Diego's ACADIA Pharmaceuticals, Inc. (ACAD) Wins FDA Breakthrough Therapy Designation For NUPLAZID™ 9/3/2014
Early Phase 3 Data Suggest Sanofi (France) (SAN.PA), Regeneron Pharmaceuticals, Inc. (REGN) Drug May Halve Heart Risk 9/3/2014
RedHill Biopharma Ltd. (RDHL) Initiates Phase 3 Study Of RHB-102 For Gastroenteritis 9/3/2014
CEL-SCI (CVM) Enrolls 20 Patients In August In Its Phase 3 Immunotherapy Head And Neck Cancer Trial 9/3/2014
Celsion Corporation (CLSN) Announces Enrollment Of First Patient In Global Phase 3 OPTIMA Study Of Thermodox® In Primary Liver Cancer 9/3/2014
Aerie Pharmaceuticals, Inc. (AERI) Initiates Phase 3 Safety-Only Registration Trial in Canada Of Rhopressa™ In Patients With Glaucoma 9/3/2014
TetraPhase Pharmaceuticals Announces Positive Oral Dosing Data From Lead-in of IGNITE 2 Phase 3 Trial Of Eravacycline In cUTI Support Advancement To Pivotal Portion 9/3/2014
Daiichi Sankyo Company, Limited Release: Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes 9/3/2014
Hatchtech Announces Successful Phase 3 Study Results For Xeglyze™ Lotion 9/2/2014
Macrocure (MCUR) Completes Enrollment In Pivotal Phase 3 Clinical Trial Of Curexcell In Diabetic Foot Ulcers 9/2/2014
Sophiris Bio Inc. (SPHS) Reports Completion Of Enrollment In The "PLUS-1" Phase 3 Trial Of PRX302 For Benign Prostatic Hyperplasia 9/2/2014
Teva Pharmaceutical Industries Limited (TEVA)’s Reslizumab Delivers Clinically And Statistically Significant Reduction In Asthma Exacerbations In Two Pivotal Phase 3 Studies 9/2/2014
XBiotech USA, Inc. Halts Cancer Study On Positive Phase 3 Results 9/2/2014
Ampio Pharmaceuticals, Inc. (AMPE) Release: Update On The Phase 3 Multicenter, Double-Blind STEP Study Of Ampion™ For Osteoarthritis Of The Knee 9/2/2014
Birken Announces Positive Results Of Phase 3 Trials With Oleogel-S10 For Accelerated Wound Healing In Patients With Partial Thickness Wounds 9/2/2014
Amgen (AMGN)'s Cholesterol Lowering Drug Succeeds In Phase 3 Trial 8/29/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 3 Study Of ISIS-APOCIII Rx In Patients With FCS 8/28/2014
FDA Grants Amgen (AMGN) Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure 8/27/2014
RedHill Biopharma Ltd. (RDHL) Provides Update On Expansion Of Ongoing RHB-105 Phase 3 Study, Targeting Broadened H. Pylori Indication Authorized By FDA 8/27/2014
ZS Pharma (ZSPH) To Present Late-Breaking Abstract Data From Phase 3 Trial Of ZS-9 In State Of The Art And Featured Research Session Oral Presentation At European Society of Cardiology Congress 8/26/2014
The Neurocritical Care Society Announces Trial Results & New Guidelines At Their 2014 Annual Meeting 8/26/2014
Regado Biosciences, Inc. (RGDO) Permanently Halts Enrollment In Lead Drug Trial 8/26/2014
Regeneron Pharmaceuticals, Inc. (REGN) And Sanofi (France) (SAN.PA) To Present Results From Four Phase 3 Alirocumab Trials In Hot Line Session At ESC Congress 2014 8/25/2014
La Jolla Pharmaceutical Company (LJPC) Announces First Patient Enrolled In Clinical Trial Of LJPC-501 In Hepatorenal Syndrome 8/25/2014
Adocia Launches Phase III Clinical Study In India Of Treatment For Diabetic Foot Ulcer 8/25/2014
Janssen Research & Development Release: Data on XARELTO® At ESC Congress 2014 Hot Line Session Premieres First Prospective Study Of A Factor Xa Inhibitor In Elective Cardioversion 8/25/2014
Update: OncoGenex Pharmaceuticals Inc. (OGXI) Phase 3 ENSPIRIT Trial Continuing As Planned 8/22/2014
Eli Lilly and Company (LLY)'s Psoriasis Drug Ixekizumab Succeeds In Late-Stage Studies 8/21/2014
Long-Acting Version Of Baxter International, Inc. (BAX)'s Hemophilia A Drug BAX 855 Succeeds In Study 8/21/2014
Amicus Therapeutics, Inc. (FOLD) Rockets On Positive Phase 3 Study Data For Rare Disease Drug 8/21/2014
Good News For Amgen (AMGN) As Parathyroid Drug AMG 416 Succeeds In Phase 3 Study 8/20/2014
CEL-SCI (CVM) Expands Its Global Phase 3 Immunotherapy Head And Neck Cancer Trial Into Centre Hospitalier Universitaire De Quebec In Canada 8/19/2014
Actavis (ACT) Reports Positive Top-Line Data From Two Ceftazidime-Avibactam Late-Stage Trials 8/19/2014
Auspex Pharmaceuticals Completes Enrollment In Phase 3 Registration Clinical Trial Of SD-809 In Chorea Associated With Huntington's Disease 8/18/2014
Amgen (AMGN) Drops After Hours On Failed Phase 3 Multiple Myeloma Trial 8/18/2014
Supernus Pharmaceuticals (SUPN) Snags FDA Fast Track Designation For ADHD Drug SPN-810 8/15/2014
FDA Accepts CorMedix (CRMD) Pivotal Phase 3 Study Protocol 8/15/2014
AstraZeneca PLC (AZN) Starts Late-Stage Asthma Drug Trial 8/14/2014
Taxus Cardium (CRXM) Announces Biological And Clinical Advances In Angiogenic Gene Therapy For Heart Disease In Journal Of Cardiovascular Pharmacology 8/13/2014
Cardium Therapeutics, Inc. (CXM) Announces Review In Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted' 8/13/2014
Mologen AG (MOLGF.PK): Preparation And Launch Of New Studies Characterized The First Half-Year 2014 8/13/2014
AstraZeneca PLC (AZN) Gets A Pipeline Boost From Good Phase 3 Gout Drug Results 8/13/2014
Northwest Biotherapeutics (NWBO) Corrects Ongoing False Claims, Phase 3 Dcvax®-L Trial Is Alive And Well 8/13/2014
Cempra Initiates Phase 3 Clinical Trial In Patients With Uncomplicated Gonorrhea Infection 8/12/2014
Juventas Therapeutics, Inc. Completes Enrollment Of Phase I/II RETRO-HF Trial And Demonstrates Safety For Retrograde Infusion Of JVS-100 In Patients With Heart Failure 8/12/2014
Cortendo AB: First Patient Enrolled Into Normocort Phase 3 SONICS Trial Following A Successful EU Investigator Meeting 8/12/2014
Salix Pharmaceuticals, Ltd. (SLXP) Announces Important Topline Results For Microbiome, Culture & Susceptibility, And Key Secondary Efficacy Results For TARGET 3, Rifaximin IBS-D Repeat Treatment Study 8/12/2014
Opko Health, Inc. Release: Rayaldee Phase 3 Trial Meets Primary Endpoints 8/12/2014
Tolero Pharmaceuticals And Eutropics Pharmaceuticals Announce Data Demonstrating Clinical Utility Of Praedicare Dx In Guiding New Drug Treatment Of CLL Patients 8/12/2014
Evoke Pharma, Inc. Announces Initiation Of A Thorough ECG (QT) Study For EVK-001 8/12/2014
Novartis AG (NVS) To Tout Heart Failure Data At European Society of Cardiology Congress 2014 8/12/2014
Genmab A/S (GEN.CO) Announces New Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 8/11/2014
Catalyst Pharmaceutical Partners, Inc. (CPRX) Provides Updates On Progress Of Phase 3 Firdapse Study In Patients With Lambert-Eaton Myasthenic Syndrome (LEMS) 8/11/2014
Northwest Biotherapeutics (NWBO) Provides Update About Phase 3 Dcvax®-L Trial For Gbm And "Information Arm" Compassionate Use Patients 8/11/2014
Northwest Biotherapeutics (NWBO) Obtains Approvals For Enhancements Of Phase 3 Trial Of Dcvax®-L For Gbm Brain Cancer 8/11/2014
Avillion Announces Dosing Of First Patients In Phase 3 BFORE Trial To Assess BOSULIF® (bosutinib) As First-Line Treatment For Patients With Chronic Myelogenous Leukemia 8/11/2014
CTI BioPharma Granted Fast Track FDA Status For Pacritinib 8/7/2014
Collegium Pharmaceutical, Inc. Announces Positive Top-Line Data From Phase III Study of Oxycodone DETERx®, Its Abuse-Deterrent, Extended-Release Product For Chronic Pain 8/7/2014
New Data Shows High Efficacy For Can-Fite BioPharma (CFBI)'s CF101 In Rheumatoid Arthritis And Psoriasis Patients 8/6/2014
BioDelivery Sciences International (BDSI) Provides Update On Ongoing Phase 3 Pivotal Trial For Clonidine Topical Gel For Painful Diabetic Neuropathy 8/6/2014
Hope Builds For New Novartis AG (NVS) Heart Failure Drug LCZ696 8/5/2014
Concordia Healthcare Corp (CXR.TO) Initiates Phase 3 Bile Duct Cancer Trial Using Photodynamic Therapy With PHOTOFRIN® 8/5/2014
Amgen (AMGN) Drug Kyprolis Helped Patients Live 8.7 Months Longer In Late-Stage Trial 8/5/2014
XBiotech USA, Inc. Enrolls First Patient In Phase III European Registration Study Using Xilonix™ For Treatment Of Colorectal Cancer 8/4/2014
Mologen AG (MOLGF.PK): First Approvals For Phase III IMPALA Colorectal Cancer Study 8/4/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 3 Study Of ISIS-SMN Rx In Infants With Spinal Muscular Atrophy 8/1/2014
CEL-SCI (CVM) Achieves Milestone In July With Total Of 232 Patients Enrolled To Date In Its Phase 3 Head And Neck Cancer Trial 8/1/2014
Genmab A/S (GEN.CO), GlaxoSmithKline (GSK)'s Ofatumumab Meets Primary Endpoint In Late-Stage Study 8/1/2014
New Data On Chimerix, Inc. (CMRX)'s brincidofovir Supports Safety And Antiviral Activity Against Multiple Life-Threatening DNA Viruses In Organ Transplant Recipients 7/31/2014
Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (France) (SAN.PA) Drug Alirocumab Cuts Cholesterol In Nine Late-Stage Trials 7/30/2014
Eisai Inc. (ESALF.PK) And Arena Pharmaceuticals, Inc. (ARNA) Announce Publication Of Post-Hoc Analyses Of Lorcaserin Phase 3 Clinical Trial Results In Obesity 7/30/2014
Alkermes plc (ALKS) Announces Initiation Of FORWARD-5 Clinical Study Of ALKS 5461 For Treatment Of Major Depressive Disorder 7/30/2014
Bioniche Life Sciences Inc. (BNC) Announces Submission Of Orphan Drug Designation Application For MCNA In The United States 7/29/2014
Incyte Corporation (INCY)'s Jakafi Fails to Provide RELIEF In Phase 3 Trial 7/28/2014
Celsion Corporation (CLSN) Shows Off Positive ThermoDox® Data In Primary Liver Cancer Patients 7/28/2014
TetraPhase Pharmaceuticals Completes Enrollment Of IGNITE 1 Eravacycline Phase 3 Clinical Trial in Complicated Intra-abdominal Infections 7/28/2014
Incyte Corporation (INCY) Release: Jakafi® (ruxolitinib) Product Label Expanded To Include Overall Survival Data And Additional Safety And Dosing Information 7/28/2014
Puma Biotechnology (PBYI) Shares Soar On Breast Cancer Drug Results 7/28/2014
DermaTools Biotech GmbH Release: Clinical Development Of Wound Healing Drug Dermapro® Progressing On Schedule In Europe 7/25/2014
Amgen (AMGN), Bayer HealthCare (BAY)'s Nexavar Fails Late-Stage Breast Cancer Study 7/25/2014
Kidney Dialysis Drug Phase 3 Data Boost Keryx Biopharmaceuticals (KERX)'s Hopes For U.S. Approval 7/25/2014
Bayer HealthCare AG (BAY) Release: Phase 3 Investigational Trial Of Azelaic Acid 15% Foam Meets Both Co-Primary Endpoints In Subjects With Papulopustular Rosacea 7/24/2014
Merck & Co., Inc. (MRK) Initiates Phase 3 Study Of Letermovir, An Investigational Antiviral For Prevention Of Cytomegalovirus (CMV) Infection In High-Risk Bone Marrow Transplant Patients 7/24/2014
rEVO Biologics Announces Enrollment Of First Patient In Phase 3 Trial Of Atryn® To Treat Early Onset Preeclampsia (PRESERVE-1) 7/24/2014
Aerie Pharmaceuticals, Inc. (AERI) Receives Health Canada "No Objection Letter" To Commence Phase 3 Registration Trial Of Rhopressatm In Patients With Glaucoma In Canada 7/24/2014
Pfizer Inc. (PFE) Backs Out of Funding Puma Biotechnology (PBYI) Cancer Drug Trials 7/24/2014
ViiV Healthcare: HIV Combo Therapy Candidate Fails Phase 3 7/23/2014
Major Advance In UCB Pipeline: Positive Topline Phase 3 Results For brivaracetam In Epilepsy Patients With Partial-Onset Seizures 7/23/2014
CEL-SCI (CVM) Has Been Cleared to Begin Patient Enrollment 7/23/2014
Synta Pharmaceuticals (SNTA) Announces Advancement Of Ganetespib Into Phase 3 Extension Of AML LI-1 Study For Patients With AML And High-Risk MDS 7/22/2014
Nymox Pharmaceutical (NYMX) Announces Positive Efficacy Results In Phase 3 Repeat Injection Trial Of NX-1207 For BPH 7/22/2014
Argos Therapeutics, Inc. (ARGS) Presents Data Showing The Impact Of HIV Antigen Sequence Divergence On Durable Viral Control Following Treatment With Autologous Immune Therapy 7/22/2014
Antares Pharma, Inc. (ATRS) Announces First Patient Dosed in Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males 7/22/2014
Enrollment Commences In NeuroSigma, Inc.-Sponsored Pediatric Clinical Trial For The Treatment Of Lennox-Gastaut Syndrome 7/22/2014
PSI CRO Launches A Global Phase 3 Rare Disease Trial 7/22/2014
Amgen (AMGN) Thyroid Drug AMG 416 Succeeds In Late Stage Kidney Patient Trial 7/21/2014
Proteon Therapeutics, Inc. Initiates Phase 3 Clinical Study Of PRT-201 In Patients With Chronic Kidney Disease Undergoing Surgical Placement Of An Arteriovenous Fistula For Hemodialysis 7/21/2014
Braeburn Pharmaceuticals Enrolls First Patients In Late-Stage Clinical Study Of Probuphine® For Opioid Dependence 7/21/2014
Dipexium Pharmaceuticals (DPRX) Initiates Second Of Two Pivotal Phase 3 Clinical Trials Of Locilex® In Patients With Mild Infections Of Diabetic Foot Ulcers 7/21/2014
InterMune, Inc. (ITMN) Grabs FDA Breakthough Therapy Designation For IPF Drug Pirfenidone 7/18/2014
Genmab A/S (GEN.CO) Announces Phase 3 Study Of Daratumumab In Front Line Multiple Myeloma 7/18/2014
Regeneron Pharmaceuticals, Inc. (REGN) Release: Two-Year Results From Phase 3 VIVID-DME Trial Of EYLEA® (aflibercept) Injection For The Treatment Of Diabetic Macular Edema Show Sustained Improvement In Vision 7/18/2014
Agile Therapeutics, Inc. Announces Allowance Of Additional Patent Claims For Skinfusion® 7/18/2014
Auspex Pharmaceuticals Initiates Pivotal Phase 2/3 Clinical Trial For SD-809 In Tardive Dyskinesia 7/17/2014
CEL-SCI (CVM) Expands Its Phase 3 Head And Neck Cancer Trial Into Sri Lanka 7/17/2014
Dipexium Pharmaceuticals (DPRX) Initiates Pivotal Phase 3 Clinical Trial Of Locilex® In Patients With Mild Infections Of Diabetic Foot Ulcers 7/17/2014
New England Journal Of Medicine Publishes Ipsen (IPN.PA)’s Somatuline® CLARINET® Phase III Results In Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors 7/17/2014
TauRx Therapeutics Achieves Enrollment Target In The First Of Its Two Phase III Clinical Trials Of LMTX™ In Alzheimer's Disease 7/17/2014
GlaxoSmithKline (GSK), Theravance, Inc. (THRX) Begin Pivotal Phase 3 Trial For Triple Combination Treatment 7/16/2014
Boehringer Ingelheim Corporation's Investigational Therapy Nintedanib Receives FDA Breakthrough Therapy Designation 7/16/2014
Pfizer Inc. (PFE) Hemophilia B Treatment Regimen Meets Endpoint In Phase 3 Trial 7/16/2014
Rigel Pharmaceuticals, Inc. (RIGL) Initiates Phase 3 Studies Of Fostamatinib In ITP 7/16/2014
Coherus Biosciences Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis (RaPsOdy) 7/16/2014
AVANIR Pharmaceuticals (AVNR) Announces Presentation Of Positive Early Results From Prism II Study 7/16/2014
ZS Pharma (ZSPH) Completes Patient Enrollment In ZS004, Its Second Phase 3 Study Of ZS-9 In Patients With Hyperkalemia 7/15/2014
Eli Lilly and Company (LLY) Release: New Data Shows Cognitive Impairment Precedes And Predicts Subsequent Functional Impairment In Patients With Mild Alzheimer's Disease 7/15/2014
Nymox Pharmaceutical (NYMX) Announces Completion Of Enrollment For Second BPH Re-Injection Study 7/15/2014
Aerie Pharmaceuticals, Inc. (AERI) Initiates Phase 3 Registration Trials of Rhopressa™, Novel Triple-Action Product To Lower Intraocular Pressure In Patients With Glaucoma 7/15/2014
Neos Therapeutics Announces Positive Phase 3 Study Results For Its Methylphenidate Extended-Release (XR) Oral Disintegrating Tablet (ODT) In ADHD Patients 7/15/2014
Exelixis, Inc. (EXEL) And Genentech (RHHBY)'s Melanoma Combination Drug Meets Main Goal In Phase 3 Study 7/15/2014
FDA Green Lights Starpharma Holdings Ltd's VivaGel Trial Design 7/14/2014
Basilea Pharmaceutica (BSLN.SW) Reports That Isavuconazole Receives Orphan Drug Designations In Europe For The Treatment Of Invasive Mold Infections 7/14/2014
Alcobra (ADHD) Completes Patient Recruitment In Phase 3 Clinical Trial Of MDX In Adult ADHD 7/14/2014
Synergy Pharmaceuticals Reaches Halfway Mark For The First Pivotal Phase 3 Trial Of Plecanatide In Patients With Chronic Idiopathic Constipation 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Novartis AG (NVS)'s New Drug Secukinumab Shows Promise In Two Pivotal Phase 3 Trials 7/11/2014
FDA Places Regado Biosciences, Inc. (RGDO)'s Phase 3 Revolixys Trial On Clinical Hold 7/11/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
TransTech Pharma, Inc. Announces Agreement With FDA On Special Protocol Assessment For TTP488 Phase 3 Trial In Patients With Mild Alzheimer’s Disease 7/10/2014
SillaJen Lead Product Pexa-Vec Featured In "Nature Reviews Cancer" Article Summarizing The Potential Of Oncolytic Immunotherapy 7/10/2014
Celgene (CELG)'s OTEZLA® Misses Mark In Phase 3 Spinal Arthritis Study 7/10/2014
Oxygen Biotherapeutics, Inc. (OXBT) Release: Recent Scientific Publications Highlight Potential Benefits Of Levosimendan In Cardiac Surgery And Additional Critical Care Conditions 7/9/2014
La Jolla Pharmaceutical Company (LJPC) Announces Planned Initiation Of Phase 3 Registration Program For LJPC-501 In Resistant Hypotension 7/9/2014
Vital Therapies, Inc. (VTI) (VTL) Reports On Clinical Trial Progress And EU Regulatory Advice 7/9/2014
San Diego's Otonomy, Inc. Touts Positive Data From Two Phase 3 Trials Of Auripro™ 7/8/2014
CEL-SCI (CVM) Receives Regulatory Clearance To Expand CEL-SCI’S Phase 3 Head And Neck Cancer Trial Into Austria 7/8/2014
Eli Lilly and Company (LLY) To Showcase Data From Its Alzheimer's Disease Portfolio At The Alzheimer's Association International Conference 2014 (AAIC 2014) 7/8/2014
Endo International plc (ENDP), BioDelivery Sciences International (BDSI) Painkiller BEMA® Buprenorphine Effective In Phase 3 Study 7/7/2014
RegeneRx Biopharmaceuticals, Inc. (RGRX)’s Strategic Partner G-Treebnt Preparing For Phase 3 Dry Eye Trials In Asia With RGN-259 7/7/2014
Regado Biosciences, Inc. (RGDO) Shares Nearly Halved After Announcing Trial Review; Stock Down -58.43% At Market Close (July 3, 2014) 7/7/2014
GlaxoSmithKline (GSK), Genmab A/S (GEN.CO) Leukemia Drug Ofatumumab Fails To Meet Main Trial Goal 7/2/2014
Salix Pharmaceuticals, Ltd. (SLXP) Surges On Encouraging Phase 3 Results For Rifaximin; Stock Up +13.51% At Market Close (July 1, 2014) 7/2/2014
CTI BioPharma Completes Recruitment in PERSIST-1 Pivotal Phase 3 Trial of Pacritinib for Patients with Myelofibrosis 7/1/2014



//-->